Investing at the frontier of life sciences.

Three curves have never been this steep at the same time. Populations are ageing, and with age comes chronic disease. Spending on health is moving earlier — from treatment toward prevention, and increasingly into the hands of consumers. And the cost of discovery is collapsing, as computation and new biology compress the path from hypothesis to clinic.

When demand is this durable and discovery this fast, the constraint is no longer science alone. It is judgement — knowing which science is real — and execution: getting it to the patients who need it.

That is where we work.